Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a phase II study

Journal of Clinical Oncology

Volumn 27, Issue 23, 2009, Pages 3836-3841

  Schiller, Joan H ^a   Larson, Timothy ^a   Ou, S H Ignatius ^a   Limentani, Steven ^a   Sandler, Alan ^a   Vokes, Everett ^a   Kim, Sinil ^a   Liau, Katherine ^a   Bycott, Paul ^a   Olszanski, Anthony J ^a   Von Pawel, Joachim ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; GLOSSODYNIA; HEADACHE; HOARSENESS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; INFERIOR CAVA VEIN OBSTRUCTION; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INDAZOLES; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 68949127256     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.8355     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
3. Manegold C, von Pawel J, Zatloukal P, et al: BO17704 (AVAIL): A phase III randomized study of first-line bevacizumab combined with cisplatin/gemcitabine (CB) in patients (pts) with advanced or recurrent non-squamous, non-snall cell lung cancer (NSCLC). Ann Oncol 19:viii1, 2008 (suppl; abstr LBA1)
4. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
5. Hu-Lowe DD, Zou HY, Grazzini ML, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1 to 3. Clin Cancer Res 14:7272-7283, 2008
6. Rugo HS, Herbst RS, Liu G, et al: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol 23:5474-5483, 2005
7. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
8. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181, 2003
9. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
10. Laurie SA, Gauthier I, Arnold A, et al: Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 26:1871-1878, 2008
11. Gauler TC, Besse B, Meric JB, et al: Phase II open-label study to investigate efficacy and safety of PTK787/ZK222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 25:394s, 2007 (suppl; abstr 7541)
12. Socinski MA, Novello S, Brahmer J, et al: Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008
13. Adjei AA, Molina JR, Hillman SL, et al: A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 25:396s, 2007 (suppl; abstr 7547)
14. Heymach JV, Johnson BE, Prager D, et al: Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 25:4270-4277, 2007
15. von Pawel J, Kaiser R, Eschbach C, et al: A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC). J Clin Oncol 25:418s, 2007 suppl; abstr 7635)
16. Lee D, Heymach JV: Emerging antiangiogenic agents in lung cancer. Clin Lung Cancer 7:304-308, 2006
17. Gatzemeier U, Blumenschein G, Fosella F, et al: Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24:364s, 2006 (suppl; abstr 7002)
18. Gutierrez M, Kummar Al, Allen D, et al: A phase II study of multikinase inhibitor sorafenib in patients with relapsed non-small cell lung cancer NSCLC). J Clin Oncol 26:712s, 2008 (suppl; abstr 19084)
19. Kiura K, Nakagawa K, Shinkai T, et al: A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 3:386-393, 2008
20. Arnold AM, Seymour L, Smylie M, et al: Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 25:4278-4284, 2007
21. Gridelli C, Maione P, Rossi A, et al: The role of bevacizumab in the treatment of non-small cell lung cancer: Current indications and future developments. Oncologist 12:1183-1193, 2007
22. Riely GJ, Miller VA: Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res 13:s4623-s4627, 2007
23. Roodhart JM, Langenberg MH, Witteveen E, et al: The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143, 2008
24. Dutcher J, Rixe O, Motzer RJ, et al: Levothyroxin treatment of hypothyroidism and axitinib (AG-013736) efficacy in patients with metastatic renal cell carcinoma. Presented at 33rd European Society for Medical Oncology Congress, Stockholm, Sweden, September 12-16, 2008
25. Tamaskar I, Bukowski R, Elson P, et al: Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19:265-268, 2008
26. Rini BI, Tamaskar I, Shaheen P, et al: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99:81-83, 2007
27. Rixe O, Bukowski RM, Michaelson MD, et al: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol 8:975-984, 2007
28. Rini B, Schiller J, Fruehauf J, et al: Association of diastolic blood pressure (dBP) = 90 mmHg with overall survival (OS) in patients treated with axitinib (AG-013736). J Clin Oncol 26:163s, 2008 (suppl; abstr 3543)
29. Friberg G, Kasza K, Vokes EE, et al: Early hypertension (HTN) as a potential pharmacodynamic (PD) marker for survival in pancreatic cancer (PC) patients (pts) treated with bevacizumab (B) and gemcitabine (G). J Clin Oncol 23:196s, 2005 (suppl; abstr 3020)
30. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
31. Stopeck A, Sheldon M, Vahedian M: Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 8:2798-2805, 2002
32. Veronese ML, Mosenkis A, Flaherty K: Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 24:1363-1369, 2006